Former Allergan Chairman Paul Bisaro will use his tested strategy of M&A and consolidation in his efforts to restore Impax Laboratories' fiscal health…

Mylan thought a series of recent deals would deliver future growth, but it's facing new pressures now—and may just have to rely on more M&A.

The Teva divestment rumors are true. The company wants to sell off its women’s health and European oncology and pain businesses to pay down debt.

Industry lobbying group PhRMA has cleared its decks of nearly two dozen members as it tries to distance itself from those companies most likely to catch heat…

Anyone who tuned into Allergan’s Q1 earnings call hoping for signs of big M&A to come likely left disappointed.

India’s Wockhardt saw its losses widen last year as its burgeoning regulatory issues with the FDA continue to chainsaw away at its finances.

Sanofi and Regeneron's eczema med Dupixent has stormed out of the launch gate, prompting analysts to hike their sales estimates for 2017 to as much as $…

There is an expectation that biosimilars will reap billions of dollars in saving for U.S. consumers by 2020. But adoption could be slowed by a "rebate…

Celgene’s Bob Hugin moved upstairs last year to the executive chairman’s seat, making way for Mark Alles to take his place as CEO, with a $6 million cut in pay.

Financials